Article ISI
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY  (2021)

Efficacy and safety of obeticholic acid in liver disease--A systematic review and meta-analysis

Tevethia, Harsh Vardhan; Candia, Roberto; Premkumar, Madhumita; Kumar, Pramod; Sharma, Mithun; Reddy, D. Nageshwar; Padaki, Nagaraja Rao

Abstract

Background and aims: Currently, there is no pharmacotherapy for non-alcoholic steatohepatitis (NASH), a common liver disorder. In contrast, primary biliary cholangitis (PBC) is a chronic cholestatic liver disease for which ursodeoxycholic acid (UDCA) is the drug of choice. However, 50% of PBC patients may not respond to UDCA. Obeticholic acid (OCA) is emerging as a vital pharmacotherapy for these chronic disorders. We aimed to analyse the safety and efficacy of OCA.

Más información

Título según WOS: Efficacy and safety of obeticholic acid in liver disease--A systematic review and meta-analysis
Título de la Revista: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
Volumen: 45
Número: 3
Editorial: ELSEVIER MASSON, CORP OFF
Fecha de publicación: 2021
DOI:

10.1016/J.CLINRE.2021.101675
Notas: ISI